Crossmark

Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s43046-024-00218-2

Published Online: 2024-05-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rangwala, Hussain Sohail https://orcid.org/0009-0007-2167-3481
Fatima, Hareer

Ali, Mirha

Sunder, Sailesh

Devi, Sonia

Rangwala, Burhanuddin Sohail

Abbas, Syed Raza
License Information

Text and Data Mining valid from 2024-05-06

Version of Record valid from 2024-05-06
More Information

Article History

Received: 10 October 2023

Accepted: 6 March 2024

First Online: 6 May 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below